Azhar Z. Abbasi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Azhar Z. Abbasi has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chunsheng He
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
3 shared publications - Xiao Yu Wu
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
3 shared publications - Andrew M. Rauth
Departments of Medical Biophysics and Radiation Oncology University of Toronto 610 University Ave Toronto Ontario M5G 2M9 Canada
2 shared publications - Elliya Park
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
2 shared publications - Jeffrey T. Henderson
Graduate Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, Canada
2 shared publications - Lily Yi Li
Leslie Dan Faculty of Pharmacy University of Toronto 144 College Street Toronto Ontario M5S 3M2 Canada
2 shared publications
Latest Publications
- 23 August 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (1) , e01648
A Novel Brain Penetrable Nanocarrier Delivers Brain‐Derived Neurotrophic Factor to Treat Alzheimer's Disease
Alzheimer's disease (AD) affects over 50 million people worldwide and is the sixth leading cause of death in North America with no cure and limited disease‐modifying therapies. Brain‐derived neurotrophic factor (BDNF) is a potential therapeutic agent, as it promotes the survival and synaptic plasticity of glutamatergic and GABAergic neurons in brain regions associated with cognitive and emotive decline in AD, and mice lacking BDNF exhibits hippocampal long‐term potentiation (LTP) impairment, reversible with recombinant BDNF. However, the poor blood‐brain barrier (BBB) permeability and pharmacokinetic properties of BDNF limit its clinical use. To address these limitations, a BDNF nanocarrier system is designed using a novel BBB‐permeable terpolymer (TP). This terpolymer‐based nanoparticle system (BDNF‐TPN) with optimized physiochemical properties protects BDNF in circulation and enables sufficient neuronal delivery of BDNF and neuron survival following Aβ exposure in vitro. The biodistribution and safety of BDNF‐TPN are evaluated via imaging, enzyme‐linked immunosorbent assay, hematologic, clinical biochemical, immunotoxicity, and histology tests. Biomarker studies demonstrate BDNF‐mediated neuroprotective signaling in an APP transgenic mouse model following intravenous injection of BDNF‐TPN with reduced apoptosis and neuron inflammation and increased neuronal survival and synaptic plasticity. Improved hippocampal‐dependent contextual learning in APP transgenic Alzheimer's mice is observed as determined by fear‐conditioning assay following two months of weekly treatments.
- 23 August 2025
- Published by Wiley in Advanced Healthcare Materials
- Vol. 15 (1) , e01648
A Novel Brain Penetrable Nanocarrier Delivers Brain‐Derived Neurotrophic Factor to Treat Alzheimer's Disease
Alzheimer's disease (AD) affects over 50 million people worldwide and is the sixth leading cause of death in North America with no cure and limited disease‐modifying therapies. Brain‐derived neurotrophic factor (BDNF) is a potential therapeutic agent, as it promotes the survival and synaptic plasticity of glutamatergic and GABAergic neurons in brain regions associated with cognitive and emotive decline in AD, and mice lacking BDNF exhibits hippocampal long‐term potentiation (LTP) impairment, reversible with recombinant BDNF. However, the poor blood‐brain barrier (BBB) permeability and pharmacokinetic properties of BDNF limit its clinical use. To address these limitations, a BDNF nanocarrier system is designed using a novel BBB‐permeable terpolymer (TP). This terpolymer‐based nanoparticle system (BDNF‐TPN) with optimized physiochemical properties protects BDNF in circulation and enables sufficient neuronal delivery of BDNF and neuron survival following Aβ exposure in vitro. The biodistribution and safety of BDNF‐TPN are evaluated via imaging, enzyme‐linked immunosorbent assay, hematologic, clinical biochemical, immunotoxicity, and histology tests. Biomarker studies demonstrate BDNF‐mediated neuroprotective signaling in an APP transgenic mouse model following intravenous injection of BDNF‐TPN with reduced apoptosis and neuron inflammation and increased neuronal survival and synaptic plasticity. Improved hippocampal‐dependent contextual learning in APP transgenic Alzheimer's mice is observed as determined by fear‐conditioning assay following two months of weekly treatments.
- Open Access
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Brain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways
Finding effective disease‐modifying treatment for Alzheimer's disease remains challenging due to an array of factors contributing to the loss of neural function. The current study demonstrates a new strategy, using multitargeted bioactive nanoparticles to modify the brain microenvironment to achieve therapeutic benefits in a well‐characterized mouse model of Alzheimer's disease. The application of brain‐penetrating manganese dioxide nanoparticles significantly reduces hypoxia, neuroinflammation, and oxidative stress; ultimately reducing levels of amyloid β plaques within the neocortex. Analyses of molecular biomarkers and magnetic resonance imaging‐based functional studies indicate that these effects improve microvessel integrity, cerebral blood flow, and cerebral lymphatic clearance of amyloid β. These changes collectively shift the brain microenvironment toward conditions more favorable to continued neural function as demonstrated by improved cognitive function following treatment. Such multimodal disease‐modifying treatment may bridge critical gaps in the therapeutic treatment of neurodegenerative disease.
- 19 February 2023
- Published by Wiley in Advanced Science
- Vol. 10 (12)
Open AccessBrain‐Penetrating and Disease Site‐Targeting Manganese Dioxide‐Polymer‐Lipid Hybrid Nanoparticles Remodel Microenvironment of Alzheimer's Disease by Regulating Multiple Pathological Pathways
Finding effective disease‐modifying treatment for Alzheimer's disease remains challenging due to an array of factors contributing to the loss of neural function. The current study demonstrates a new strategy, using multitargeted bioactive nanoparticles to modify the brain microenvironment to achieve therapeutic benefits in a well‐characterized mouse model of Alzheimer's disease. The application of brain‐penetrating manganese dioxide nanoparticles significantly reduces hypoxia, neuroinflammation, and oxidative stress; ultimately reducing levels of amyloid β plaques within the neocortex. Analyses of molecular biomarkers and magnetic resonance imaging‐based functional studies indicate that these effects improve microvessel integrity, cerebral blood flow, and cerebral lymphatic clearance of amyloid β. These changes collectively shift the brain microenvironment toward conditions more favorable to continued neural function as demonstrated by improved cognitive function following treatment. Such multimodal disease‐modifying treatment may bridge critical gaps in the therapeutic treatment of neurodegenerative disease.
- 15 April 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (8_Suppleme) , PO-100-100
Abstract PO-100: Theragnostic tumor-targeted manganese dioxide-loaded polymer-lipid nanoparticles for magnetic resonance image-guided radiation therapy
Background: Magnetic resonance image-guided radiation therapy (MRgRT) is a new-generation approach to improving treatment outcomes by allowing real-time precise tumor delineation that guides the radiation. However, the existing gadolinium-based contrast agents (GBCAs) are insufficient for MRgRT due to their severe side effects and rapid clearance from the tumor that requires multiple injections to maintain the signal. In addition, tumor hypoxia induced radiation resistance, which attenuates the RT efficacy. To date, there is no FDA-approved contrast agent with high safety and efficacy profile exhibiting both MR signal enhancement and RT sensitization capabilities. Based on our previous findings that manganese-dioxide nanoparticles (MDNP) can convert tumoral ROS (H2O2) into O2 to reduce hypoxia and sensitize RT, we propose the design of a novel tumor-targeting manganese-dioxide nanoparticle (MDNP) with dual MRI and RT enhancement functionalities. In this work, we evaluate the safety profile, biodistribution, in vivo clearance, MR contrast enhancement, and radiation sensitization effect of the MDNPs. Methods: Terpolymer-based MDNP (T-MDNP) were prepared by loading MnO2 precursor in a polymer-lipid matrix. Physicochemical properties and stability of NPs were determined by TEM, DLS, and zeta potential measurements. In vitro cellular uptake by cancer cells was measured via confocal microscopy. The biocompatibility and safety of the NPs was examined in vitro and in vivo. Tissue distribution, clearance, and tumor retention of T-MDNPs was evaluated using MRI and ICP. The tumoral MR signal enhancement by T-MDNP as a function of time was measured and compared with Gadavist™ (gadobutrol) in murine tumor models with human MDA-MB-231 breast or prostate PC3 xenografts. The ability of NPs to modulate tumor microenvironment (TME) and enhance RT efficacy was also evaluated. Results: The prepared T-MDNPs were 120 nm in size and exhibited excellent storage stability at room temperature and 4°C. The NPs showed negligible hemolysis effect suggesting their suitability for intravenous (IV) injection. As a result of in situ generation of Mn+2 ions via the reaction with tumoral ROS, a single dose of 70 μmole Mn/kg of body weight of T-MDNP increased tumor T1 signal by up to 1.4-fold and maintained it up to 4 hrs, while Gadavist™ was eliminated in about 30 min. The NPs were completely cleared from major organs in 72 hrs, as determined by MRI and ICP. Combination of NP treatments with RT resulted in significantly increased median survival time by 2-fold in human PC3 prostate model and 5-fold in human breast tumor model. Conclusions: Our results have demonstrated that the T-MDNPs are safe and effective as a dual MR contrast agent and radiation sensitizer. This system is promising for precise tumor margin delineation, maintaining MR signal in tumor for a duration needed for MRgRT, and improving RT efficacy. These properties make it an excellent candidate and the first-in-class entity that can be utilized with MRgRT. Citation Format: Charles Yen, Azhar Z. Abbasi, Chunsheng He, Mohammad Ali Amini, Hoyin Lip, Michael Rauth, Xiao Yu Wu. Theragnostic tumor-targeted manganese dioxide-loaded polymer-lipid nanoparticles for magnetic resonance image-guided radiation therapy [abstract]. In: Proceedings of the AACR Virtual Special Conference on Radiation Science and Medicine; 2021 Mar 2-3. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(8_Suppl):Abstract nr PO-100.
- 15 April 2021
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (8_Suppleme) , PO-100-100
Abstract PO-100: Theragnostic tumor-targeted manganese dioxide-loaded polymer-lipid nanoparticles for magnetic resonance image-guided radiation therapy
Background: Magnetic resonance image-guided radiation therapy (MRgRT) is a new-generation approach to improving treatment outcomes by allowing real-time precise tumor delineation that guides the radiation. However, the existing gadolinium-based contrast agents (GBCAs) are insufficient for MRgRT due to their severe side effects and rapid clearance from the tumor that requires multiple injections to maintain the signal. In addition, tumor hypoxia induced radiation resistance, which attenuates the RT efficacy. To date, there is no FDA-approved contrast agent with high safety and efficacy profile exhibiting both MR signal enhancement and RT sensitization capabilities. Based on our previous findings that manganese-dioxide nanoparticles (MDNP) can convert tumoral ROS (H2O2) into O2 to reduce hypoxia and sensitize RT, we propose the design of a novel tumor-targeting manganese-dioxide nanoparticle (MDNP) with dual MRI and RT enhancement functionalities. In this work, we evaluate the safety profile, biodistribution, in vivo clearance, MR contrast enhancement, and radiation sensitization effect of the MDNPs. Methods: Terpolymer-based MDNP (T-MDNP) were prepared by loading MnO2 precursor in a polymer-lipid matrix. Physicochemical properties and stability of NPs were determined by TEM, DLS, and zeta potential measurements. In vitro cellular uptake by cancer cells was measured via confocal microscopy. The biocompatibility and safety of the NPs was examined in vitro and in vivo. Tissue distribution, clearance, and tumor retention of T-MDNPs was evaluated using MRI and ICP. The tumoral MR signal enhancement by T-MDNP as a function of time was measured and compared with Gadavist™ (gadobutrol) in murine tumor models with human MDA-MB-231 breast or prostate PC3 xenografts. The ability of NPs to modulate tumor microenvironment (TME) and enhance RT efficacy was also evaluated. Results: The prepared T-MDNPs were 120 nm in size and exhibited excellent storage stability at room temperature and 4°C. The NPs showed negligible hemolysis effect suggesting their suitability for intravenous (IV) injection. As a result of in situ generation of Mn+2 ions via the reaction with tumoral ROS, a single dose of 70 μmole Mn/kg of body weight of T-MDNP increased tumor T1 signal by up to 1.4-fold and maintained it up to 4 hrs, while Gadavist™ was eliminated in about 30 min. The NPs were completely cleared from major organs in 72 hrs, as determined by MRI and ICP. Combination of NP treatments with RT resulted in significantly increased median survival time by 2-fold in human PC3 prostate model and 5-fold in human breast tumor model. Conclusions: Our results have demonstrated that the T-MDNPs are safe and effective as a dual MR contrast agent and radiation sensitizer. This system is promising for precise tumor margin delineation, maintaining MR signal in tumor for a duration needed for MRgRT, and improving RT efficacy. These properties make it an excellent candidate and the first-in-class entity that can be utilized with MRgRT. Citation Format: Charles Yen, Azhar Z. Abbasi, Chunsheng He, Mohammad Ali Amini, Hoyin Lip, Michael Rauth, Xiao Yu Wu. Theragnostic tumor-targeted manganese dioxide-loaded polymer-lipid nanoparticles for magnetic resonance image-guided radiation therapy [abstract]. In: Proceedings of the AACR Virtual Special Conference on Radiation Science and Medicine; 2021 Mar 2-3. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(8_Suppl):Abstract nr PO-100.